-+ 0.00%
-+ 0.00%
-+ 0.00%

Slovenia Endorses Maximum Allowed Price for Oncopeptides' Multiple Myeloma Drug Pepaxti

MT Newswires·08/17/2026 06:10:57
Listen to the news
06:10 AM EDT, 08/17/2026 (MT Newswires) -- Oncopeptides (ONCO.ST) said Monday that Slovenia's medicinal products and medical devices regulator endorsed a maximum allowed price for Pepaxti in patients with multiple myeloma. The pricing determination by the Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices is a prerequisite for the Swedish biotech company to start formal market access and reimbursement negotiations with the Health Insurance Institute of Slovenia. Oncopeptides noted that Slovenia is a key reference pricing market in the Central and Eastern Europe region.